Enhanced Effectiveness of Combination Therapy in Reducing Albuminuria for CKD and Type 2 Diabetes Patients
A new study shows that combination therapy with finerenone and empagliflozin significantly reduces albuminuria in CKD patients with type 2 diabetes, potentially transforming treatment approaches.
Recent findings from the CONFIDENCE trial highlight that combining finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, with the SGLT2 inhibitor empagliflozin results in significantly greater reductions in albuminuria among patients suffering from chronic kidney disease (CKD) with type 2 diabetes (T2D). Presented at the 62nd ERA Congress and published in the New England Journal of Medicine, this study suggests a promising shift in treatment strategy for high-risk CKD patients.
Albuminuria, an early marker of CKD, indicates disease progression and increased cardiovascular risk. Both finerenone and empagliflozin have independently demonstrated benefits in delaying kidney deterioration and improving cardiovascular health. This trial is groundbreaking as it investigates the impact of using both agents simultaneously, aiming for superior kidney protection.
The phase 2, multicenter, double-blind trial involved 818 adults across 143 international sites, all with CKD and T2D, and a urinary albumin-to-creatinine ratio (UACR) between 100 and 5,000 mg/g. Participants were assigned to receive either a placebo, finerenone alone (10 or 20 mg), empagliflozin alone (10 mg), or a combination of finerenone and empagliflozin. Dosing adjustments were made based on baseline kidney function. All participants were on maximally tolerated doses of renin-angiotensin system inhibitors.
Results at 180 days showed that the combination therapy group experienced a median UACR reduction of 52%, significantly greater than the reductions seen with either drug alone—29% more than finerenone and 32% more than empagliflozin alone. This early additive effect underscores the potential of dual therapy to more effectively reduce kidney-related biomarkers.
Lead researcher Dr. Rajiv Agarwal emphasized that early, combined intervention offers substantial improvement in UACR, which is closely linked to kidney and cardiovascular outcomes. The combination therapy was well-tolerated, with low rates of adverse events such as hypotension, acute kidney injury, or hyperkalemia.
This innovative approach advocates for a paradigm shift towards proactive dual-pathway management earlier in CKD and T2D care, potentially leading to better long-term outcomes for patients at high risk of deterioration and cardiovascular events.
For detailed insights, refer to the study published in the New England Journal of Medicine (2025): [DOI: 10.1056/NEJMoa2410659].
Source: https://medicalxpress.com/news/2025-06-combination-therapy-superior-efficacy-albumin.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Long-Term Antidepressant Use Linked to Increased Withdrawal Symptoms, Study Reveals
Research shows that long-term antidepressant users are more prone to withdrawal symptoms, with effects lasting longer and being more severe. Careful tapering and professional guidance are essential for safe discontinuation.
Innovative Biobattery Offers New Hope for Drug-Free Cancer Treatment by Tumor Shrinkage
A novel biobattery developed by researchers at the University of Wollongong and Jilin University shows promise in shrinking tumors and enabling drug-free cancer immunotherapy using bioelectrochemical processes.
Impact of Marijuana Legalization on Traditional Prescription Drug Use
Research reveals that recreational cannabis legalization has led to a significant reduction in prescription drug claims in small insurance markets, highlighting shifting healthcare patterns.
The Role of Balanced Excitatory and Inhibitory Neurons in Brain Memory Processing
New insights reveal that the balance between excitatory and inhibitory neurons is crucial for efficient memory storage and processing in the brain, advancing our understanding of neural network dynamics.